Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.47 |
| ▸ | CTSA | P10619 | 2/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | TPH1 | P17752 | 6/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15947122 | 0.91 | MMEL1 (0.59) | MMEL1FFAR4CTSASLC9A1TPH1 | |
| SCHEMBL2873273 | 0.88 | MMEL1 (0.53) | MMEL1FFAR4CTSASLC9A1TPH1 | |
| Hydrochloric Acid SCHEMBL2873276 | 0.87 | MMEL1 (0.52) | MMEL1FFAR4CTSASLC9A1TPH1 | |
| Hydrochloric Acid SCHEMBL2873271 | 0.87 | MMEL1 (0.52) | MMEL1FFAR4CTSASLC9A1TPH1 | |
| Hydrochloric Acid SCHEMBL1912556 | 0.86 | MMEL1 (0.64) | MMEL1FFAR4CTSATPH1MME | |
| SCHEMBL15948912 | 0.83 | MMEL1 (0.51) | MMEL1FFAR4CTSASLC9A1NR3C1 | |
| SCHEMBL15948922 | 0.82 | MMEL1 (0.59) | MMEL1FFAR4CTSASLC9A1NR3C1 | |
| Hydrochloric Acid SCHEMBL2706266 | 0.80 | MMEL1 (0.54) | MMEL1FFAR4CTSASLC9A1TPH1 | |
| SCHEMBL12317516 | 0.78 | MMEL1 (0.50) | MMEL1FFAR4CTSASLC9A1TPH1 | |
| SCHEMBL12939813 | 0.77 | MMEL1 (0.50) | MMEL1FFAR4SLC9A1TPH1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102635-B2 | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| WO-2014126972-A1 | SUBSTITUTED BISPHENYL BUTANOIC ACID DERIVATIVES AS NEP INHIBITORS WITH IMPROVED IN VIVO EFFICACY | NOVARTIS AG (CH) | 2014-08-21 | — | — | WO | disclosed |
| US-20140228415-A1 | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo Efficacy | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228415-A1 | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo Efficacy | MME, REN, ACE | MMEL1 424/4885FFAR4 787/4885CTSA 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.